Johnson & Johnson

NYSE:JNJ   3:19:39 PM EDT
143.25
-1.99 (-1.37%)
Regulatory, Other Pre-Announcement

J&J Reports Q3 Adjusted Earnings Per Share Of $2.20

Published: 10/13/2020 10:54 GMT
Johnson & Johnson (JNJ) - Johnson & Johnson Reports 2020 Third-quarter Results.
Q3 Adjusted Earnings per Share $2.20.
Q3 Earnings per Share $1.33.
Q3 Earnings per Share Estimate $1.98 -- Refinitiv Ibes Data (analyst estimates).
Q3 Revenue $21.1 Billion Versus Refinitiv Ibes Estimate of $20.2 Billion.company Increasing Guidance for Full Year Reported Sales by $1.0 Billion and Adjusted EPS by $0.15.
Sees FY Adjusted EPS $7.95 to $8.05.
Sees FY Adjusted Operational Sales Up 0.5% to 1.5%.
Sees FY Operational Sales $82.0 Billion to $82.8 Billion.
Qtrly Worldwide Imbruvica Sales $1.03 Billion Versus $921 Million.
Qtrly Sales Rise Despite Estimated Negative Impact of Covid-19 Pandemic.
Qtrly Non-GAAP Medical Devices Sales $6.15 Billion Versus $6.38 Billion Reported Last Year.
Qtrly Worldwide Darzalex Sales $1.01 Billion Versus $765 Million.
Qtrly Litigation Expense $1.48 Billion Versus $4 Billion Reported Last Year.
Qtrly Worldwide Remicade Sales $921 Million Versus $1.14 Billion Reported Last Year.
Consumer Health Qtrly Sales Growth Driven by U.S. Growth in Over-the-counter Products Incl.
Tylenol Analgesics, Digestive Health Products, Among Others.
Qtrly Net Other Expense $1.2 Billion Versus $4.21 Billion.